211 related articles for article (PubMed ID: 21439833)
41. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
42. Structure-activity relationship studies of novel glycosphingolipids that stimulate natural killer T-cells.
Tashiro T
Biosci Biotechnol Biochem; 2012; 76(6):1055-67. PubMed ID: 22790924
[TBL] [Abstract][Full Text] [Related]
43. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
44. The in vitro proliferation and cytokine production of Vα24+Vβ11+ natural killer T cells in patients with systemic lupus erythematosus.
Yu XM; Wang XF
Chin Med J (Engl); 2011 Jan; 124(1):61-5. PubMed ID: 21362309
[TBL] [Abstract][Full Text] [Related]
45. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
46. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
47. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
48. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors.
Pellicci DG; Clarke AJ; Patel O; Mallevaey T; Beddoe T; Le Nours J; Uldrich AP; McCluskey J; Besra GS; Porcelli SA; Gapin L; Godfrey DI; Rossjohn J
Nat Immunol; 2011 Jul; 12(9):827-33. PubMed ID: 21804559
[TBL] [Abstract][Full Text] [Related]
49. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
50. Leishmania donovani glycosphingolipid facilitates antigen presentation by inducing relocation of CD1d into lipid rafts in infected macrophages.
Karmakar S; Paul J; De T
Eur J Immunol; 2011 May; 41(5):1376-87. PubMed ID: 21425159
[TBL] [Abstract][Full Text] [Related]
51. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.
Li Y; Girardi E; Wang J; Yu ED; Painter GF; Kronenberg M; Zajonc DM
J Exp Med; 2010 Oct; 207(11):2383-93. PubMed ID: 20921281
[TBL] [Abstract][Full Text] [Related]
52. A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.
Wang J; Guillaume J; Janssens J; Remesh SG; Ying G; Bitra A; Van Calenbergh S; Zajonc DM
J Biol Chem; 2019 Sep; 294(39):14345-14356. PubMed ID: 31391251
[TBL] [Abstract][Full Text] [Related]
53. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR.
Wun KS; Borg NA; Kjer-Nielsen L; Beddoe T; Koh R; Richardson SK; Thakur M; Howell AR; Scott-Browne JP; Gapin L; Godfrey DI; McCluskey J; Rossjohn J
J Exp Med; 2008 Apr; 205(4):939-49. PubMed ID: 18378792
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of a 2"-deoxy-β-GalCer.
Thakur MS; Khurana A; Kronenberg M; Howell AR
Molecules; 2014 Jul; 19(7):10090-102. PubMed ID: 25014535
[TBL] [Abstract][Full Text] [Related]
55. Optical Control of Cytokine Production Using Photoswitchable Galactosylceramides.
Hartrampf N; Seki T; Baumann A; Watson P; Vepřek NA; Hetzler BE; Hoffmann-Röder A; Tsuji M; Trauner D
Chemistry; 2020 Apr; 26(20):4476-4479. PubMed ID: 31788876
[TBL] [Abstract][Full Text] [Related]
56. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
Satoh M; Iwabuchi K
Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
[TBL] [Abstract][Full Text] [Related]
57. Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production.
Liang PH; Imamura M; Li X; Wu D; Fujio M; Guy RT; Wu BC; Tsuji M; Wong CH
J Am Chem Soc; 2008 Sep; 130(37):12348-54. PubMed ID: 18712867
[TBL] [Abstract][Full Text] [Related]
58. Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy.
Joshi SK; Lang GA; Larabee JL; Devera TS; Aye LM; Shah HB; Ballard JD; Lang ML
PLoS Pathog; 2009 Sep; 5(9):e1000588. PubMed ID: 19779559
[TBL] [Abstract][Full Text] [Related]
59. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
[TBL] [Abstract][Full Text] [Related]
60. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
Venkataswamy MM; Porcelli SA
Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
